CryoPort, Inc. (NASDAQ:CYRX) Receives $12.83 Consensus PT from Analysts

Shares of CryoPort, Inc. (NASDAQ:CYRX) have been assigned a consensus rating of “Moderate Buy” from the ten analysts that are presently covering the firm, MarketBeat reports. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and eight have assigned a buy rating to the company. The average 12-month price objective among analysts that have updated their coverage on the stock in the last year is $12.9444.

CYRX has been the topic of several recent research reports. Needham & Company LLC lifted their price target on CryoPort from $12.00 to $13.00 and gave the company a “buy” rating in a research note on Wednesday. UBS Group increased their price objective on CryoPort from $11.00 to $12.50 and gave the stock a “buy” rating in a report on Wednesday, November 5th. Finally, Weiss Ratings restated a “sell (d+)” rating on shares of CryoPort in a research note on Monday, December 29th.

CryoPort Stock Performance

Shares of CYRX stock opened at $8.74 on Thursday. The company has a debt-to-equity ratio of 0.40, a quick ratio of 15.01 and a current ratio of 15.77. CryoPort has a 52 week low of $4.63 and a 52 week high of $11.45. The company’s 50 day moving average price is $9.49 and its two-hundred day moving average price is $9.40. The company has a market capitalization of $437.60 million, a P/E ratio of 6.62 and a beta of 1.69.

CryoPort (NASDAQ:CYRX) last issued its quarterly earnings data on Tuesday, March 3rd. The company reported ($0.21) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.19) by ($0.02). CryoPort had a negative return on equity of 8.33% and a net margin of 42.35%.The company had revenue of $45.45 million for the quarter, compared to the consensus estimate of $42.92 million. On average, analysts expect that CryoPort will post -0.99 earnings per share for the current fiscal year.

Insider Activity at CryoPort

In related news, Director Ramkumar Mandalam sold 11,570 shares of CryoPort stock in a transaction dated Wednesday, December 10th. The stock was sold at an average price of $9.99, for a total value of $115,584.30. Following the sale, the director owned 80,758 shares of the company’s stock, valued at approximately $806,772.42. The trade was a 12.53% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 10.00% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On CryoPort

A number of large investors have recently added to or reduced their stakes in the business. Assenagon Asset Management S.A. increased its stake in CryoPort by 37.4% in the third quarter. Assenagon Asset Management S.A. now owns 1,498,774 shares of the company’s stock valued at $14,208,000 after acquiring an additional 408,263 shares during the last quarter. SG Americas Securities LLC boosted its holdings in shares of CryoPort by 663.2% in the 3rd quarter. SG Americas Securities LLC now owns 127,280 shares of the company’s stock valued at $1,207,000 after purchasing an additional 110,602 shares in the last quarter. Y Intercept Hong Kong Ltd bought a new position in shares of CryoPort in the 2nd quarter valued at $292,000. Bullseye Asset Management LLC raised its holdings in shares of CryoPort by 23.0% during the 2nd quarter. Bullseye Asset Management LLC now owns 260,168 shares of the company’s stock worth $1,941,000 after buying an additional 48,605 shares in the last quarter. Finally, Thematics Asset Management raised its holdings in shares of CryoPort by 12.8% during the 2nd quarter. Thematics Asset Management now owns 1,914,885 shares of the company’s stock worth $14,285,000 after buying an additional 216,937 shares in the last quarter. Institutional investors own 92.90% of the company’s stock.

About CryoPort

CryoPort, Inc (NASDAQ: CYRX) is a global provider of temperature-controlled logistics solutions for the life sciences industry. The company specializes in cryogenic shipping for critical biological materials, supporting the development, clinical testing and commercialization of cell and gene therapies, biologics, vaccines and reproductive medicine. By offering end-to-end supply chain management, CryoPort helps ensure the integrity and viability of temperature-sensitive products from point of origin to destination.

CryoPort’s product portfolio includes proprietary cryogenic dry shippers, advanced active and passive thermal packaging, and real-time data monitoring platforms.